← Leaderboards
Amira Barkal
Stanford University
$115,845
Attributed
$115,845
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $43.5K · FY2018–20$50K$37.5K$25K$12.5K$0
'18
'19
'20
Funding mix
By agency
NIH$115,845 · 1
By mechanism
F30$115,845 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Alexander D Boiko$3,037,060
- Peter Poon-Hang Lee$6,837,790
- Kenan Christopher Garcia$35,612,900
- Melanie Hayden Gephart$6,763,817
- Peter R Parham$35,417,272
Others in their field
Other Emerging Leaders on “Equilibrium”
- Arnab Kumar Chatterjee · Washington University$22,541,385
- Oliver Brand · Emory University$18,504,645
- Alan D. Palkowitz · Indiana University Indianapolis$17,630,798
- James N Campbell · Centrexion Therapeutics Corporation$8,662,635
- Kathleen E Cullen · Jackson Laboratory$8,434,977
- Gary Fanger · Rise Therapeutics, Llc$8,257,203
Research focus
EquilibriumAdaptive Immune ResponseAntibodiesEngineeringAnti-CancerAscitesBaseAnti-Cancer TherapeuticAnti-Tumor Immune ResponseCancer CellCancer Cell LineAntitumor ResponseCancer ImmunotherapyCancer ModelCancer TherapyCandidate Disease GeneCd47 GeneBlocking AntibodiesBreast Cancer Cell LineCombatCrispr/Cas TechnologyCrispr ScreenEatingGene Pool
Grant awards (3)
Targeting the Major Histocompatibility Class I-LILRB1 signaling axis for cancer immunotherapy by macrophages$29,275
F30 · FY2020 · CA · contact PI
Targeting the Major Histocompatibility Class I-LILRB1 signaling axis for cancer immunotherapy by macrophages$43,531
F30 · FY2019 · CA · contact PI
Targeting the Major Histocompatibility Class I-LILRB1 signaling axis for cancer immunotherapy by macrophages$43,039
F30 · FY2018 · CA · contact PI